Nivolumab biosimilar (Biocad)

纳武利尤单抗生物类似药（Biocad）

Report date: 2025/02/18 11:33:20

Base Information

Drug NameNivolumab biosimilar (Biocad)
Drug Alias NameBCD-263
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Biosimilar
Mechanisms of ActionProgrammed cell death protein 1 inhibitors
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsSkin MelanomaMelanoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryPakistanRussian FederationBelarus
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesBIOCAD JSC
China Registration ClassN/A

Develop Information

Active CompaniesBIOCAD JSC
Inactive CompaniesN/A
Active IndicationsSkin MelanomaMelanoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A